Cell Therapy News Volume 24.28 | Aug 21 2023

    By
    Bob
    -
    0
    16








    2023-08-21 | CTN 24.28


    Cell Therapy News by STEMCELL Technologies
    Vol. 24.28 – 21 August, 2023
    TOP STORY

    Cultivated Autologous Limbal Epithelial Cell (CALEC) Transplantation: Development of Manufacturing Process and Clinical Evaluation of Feasibility and Safety

    To treat unilateral limbal stem cell (LSC) deficiency, scientists developed CALEC using an innovative xenobiotic-free, serum-free, antibiotic-free, two-step manufacturing process for LSC isolation and expansion onto human amniotic membrane.
    [Science Advances]

    Full ArticlePress Release
    This webinar provides insights and techniques for efficient leukopak sample processing and streamlined cell isolation.
    PUBLICATIONSRanked by the impact factor of the journal

    Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

    The authors reported that solid tumors released small extracellular vesicles that carried both targeted tumor antigens and the immune checkpoint protein PD-L1.
    [Cancer Research]

    Abstract
    Graphical Abstract

    Lonizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering

    Investigators reported the development of an ionizable lipid nanoparticle platform for simultaneous therapeutic mRNA expression and RNAi-mediated transient gene knockdown in T cells.
    [Advanced Healthcare Materials]

    Abstract

    Highly Proliferative and Hypodifferentiated CAR-T Cells Targeting B7–H3 Enhance Antitumor Activity against Ovarian and Triple-Negative Breast Cancers

    Researchers proposed a combination of elements for the construction of superior pluripotent CAR-T cells to provide an effective strategy for the treatment of intractable solid tumors.
    [Cancer Letters]

    AbstractGraphical Abstract

    Hypoxia-Regulated Secretion of IL-12 Enhances Antitumor Activity and Safety of CD19 CAR-T Cells in the Treatment of Diffuse Large B Cell Lymphoma

    Scientists suggested that armed CD19 CARs with hypoxia-controlled interleukin (IL)-12 might be a promising and safer approach for treating Diffuse Large B cell Lymphoma.
    [Molecular Therapy Oncolytics]

    AbstractGraphical Abstract

    Human Multi-Chimeric Cell (HMCC) Therapy as a Novel Approach for Tolerance Induction in Transplantation

    Researchers introduced a novel HMCC line created by fusion of umbilical cord blood cells as an alternative therapeutic approach to bone marrow transplantation and tolerance induction in solid organ and vascularized composite allotransplantation transplants.
    [Stem Cell Reviews and Reports]

    Full ArticleGraphical Abstract

    Enhanced Cardioprotective Activity of Ferulic Acid-Loaded Solid Lipid Nanoparticle in an Animal Model of Myocardial Injury

    The authors examined the cardioprotective effects of ferulic acid (FA) and FA nanostructured solid lipid nanoparticles in an isoproterenol induced myocardial infarction model.
    [Toxicology and Applied Pharmacology]

    Abstract

    In Vivo Tracking of Adenoviral-Transduced Iron Oxide-Labeled Bone Marrow-Derived Dendritic Cells Using Magnetic Particle Imaging

    Investigators described a popliteal lymph node-focused magnetic particle imaging scan to quantify dendritic cell in vivo migration accurately and consistently.
    [European Radiology Experimental]

    Full Article

    Nanoparticle Delivery of Immunostimulatory Alu RNA for Cancer Immunotherapy

    Researchers performed a bioinformatic analysis of adenosine-to-inosine (A-to-I) RNA editing in human melanoma samples and determined that pre-therapy levels of A-to-I RNA editing negatively correlate with survival times.
    [Cancer Research Communications]

    Abstract
    Request your free copy of the 'Production of Chimeric Antigen Receptor T Cells' Wallchart
    REVIEWS

    Targeting Cancer with mRNA–Lipid Nanoparticles: Key Considerations and Future Prospects

    Scientists describe the opportunities of using mRNA–lipid nanoparticles in oncology applications and discuss the challenges for successfully translating the findings of preclinical studies of these nanoparticles into the clinic.
    [Nature Reviews Clinical Oncology]

    Abstract

    Chimeric Antigen Receptor-Modified T Cells Therapy in Prostate Cancer: A Comprehensive Review on the Current State and Prospects

    The authors elucidate different types of prostate tumor-associated antigen targets, such as prostate-specific membrane antigen and prostate stem cell antigen and their effects.
    [Heliyon]

    Full ArticleGraphical Abstract
    INDUSTRY AND POLICY NEWS

    Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis

    Artiva Biotherapeutics, Inc. announced that the US FDA has cleared the company’s Investigational New Drug (IND) application for AlloNK®, in combination with rituximab for the treatment of systemic lupus erythematosus in patients with active lupus nephritis.
    [Artiva Biotherapeutics Inc.]

    Press Release

    UTHSC Researcher Awarded $1.56 Million for Accelerating Progress in Stem Cell Treatment of PTOA

    Hongsik Jake Cho, PhD, associate professor at the University of Tennessee Health Science Center (UTHSC), recently received a $1.56 million Rehabilitation Research and Development Award from the US Department of Veterans Affairs to research next-generation treatments for post-traumatic osteoarthritis.
    [University of Tennessee Health Science Center]

    Press Release

    2023 GSK Chairman’s Prize Recognizes Chi Nguyen, Research on Gut Health

    Chi Nguyen, a PhD student attending the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), has been awarded the 2023 Chairman’s Prize.
    [Memorial Sloan Kettering Cancer Center]

    Press Release
    FEATURED EVENT

    AACR Special Conference: Pancreatic Cancer

    September 27 – 30, 2023
    Boston, Massachusetts, United States

    > See All Events

    JOB OPPORTUNITIES

    Associate Professor – Cancer Immunology and Immunotherapy

    Baylor College of Medicine – Houston, Texas, United States

    Research Associate – Recombinant Protein

    Creative Biolabs – New York, New York, United States

    Assistant Professor – Immunology

    Harvard Medical School – Boston, Massachusetts, United States

    Research Associate – T Cell Immunotherapy

    City of Hope – Duarte, California, United States

    Principal Investigators – Molecular Cell Science

    Center for Excellence in Molecular Cell Science – Shanghai, China

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cell Therapy News Twitter